Research HDIs
Related Resources for this page:
- Future Directions
- Antibody-Drug Conjugates
- Antibody-Drug conjugates
- Glycoengineered Antibodies
- Non-Antibody Biologics
- Targeted Small Molecules
- Traditional Monoclonal Antibodies
- Anti-EGFL7
- Glossary
- Gastric Cancer
- HER Signaling
- HER1/EGFR as a therapeutic target
- HER2:HER3 dimer
- HER2 as a therapeutic target
- HER3 as a therapeutic target
- Melanoma
- Angiogenic Signaling
- Inhibition of HER2 dimerization
- Therapeutic potential of HER pathways
- Slide decks and videos
- What are the strategies for inhibiting the VEGF pathway?
Dimerization Video
Potential Role of Dimerization
HER2+ Breast Cancer Slide Decks
Comprehensive overview of HER2 Dimerization Inhibitors (HDIs)
New: HER2 Dimerization iTunes app
Explore the potential of HER2 dimerization inhibition
View all downloadable resources
Share
What makes HER2 different?
HER2: a key receptor for dimerization
HER2 is a key receptor for dimerization. HER2 is the only receptor that exists in an "open" conformation, ready to dimerize with other HER family members. Because HER2 is continually ready to dimerize, the overexpression of HER2 promotes the excessive formation of HER2 dimers.3
Preclinical studies also show that HER2-containing dimers have increased signaling potency relative to those without HER2.2